Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Gregor Werba

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1464-9065; OpenAlex author ID A5056053364. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
51
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 4 papers · 2024: 1 paper

Papers 11

  1. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the T… Co-author DOI 10.1158/2326-6066.cir-23-1073↗
  2. Correction to: BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer. Co-author DOI 10.1038/s41388-023-02606-9↗
  3. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Co-author DOI 10.1038/s41467-023-36296-4↗
  4. Author Correction: Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Co-author DOI 10.1038/s41467-023-39680-2↗
  5. POLQ inhibition elicits an immune response in homologous recombination-deficient pancreatic adenocarcinoma via cGAS/STING signaling. Co-author DOI 10.1172/jci165934↗
  6. BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer. Co-author DOI 10.1038/s41388-022-02425-4↗
  7. Missing links - epigenetic regulators of the pancreatic cancer-associated inflammation. Co-author DOI 10.1042/cs20210181↗
  8. The biological underpinnings of therapeutic resistance in pancreatic cancer. First author DOI 10.1101/gad.348523.121↗
  9. The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Co-author DOI 10.1158/2159-8290.cd-17-1134↗
  10. Phosphorylation of STAT3 correlates with HER2 status, but not with survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/apm.12194↗
  11. A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer. Co-author PMID 24778046↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Diane M. Simeone · 5 shared papers, 2021–2024 · strength 0.74
  2. Tamas A. Gonda · 3 shared papers, 2021–2023 · strength 0.55
  3. Grace Oh · 3 shared papers, 2023 · strength 0.41
  4. Despoina Kalfakakou · 3 shared papers, 2023 · strength 0.41
  5. Paul E. Oberstein · 3 shared papers, 2023–2024 · strength 0.40
  6. Deirdre Jill Cohen · 3 shared papers, 2018–2023 · strength 0.29
  7. Berk Aykut · 3 shared papers, 2018–2023 · strength 0.29
  8. Brian E. Diskin · 3 shared papers, 2018–2023 · strength 0.29
  9. George Miller · 3 shared papers, 2018–2023 · strength 0.29
  10. Aristotelis Tsirigos · 2 shared papers, 2023 · strength 0.27
  11. Mara H. Sherman · 2 shared papers, 2023 · strength 0.27
  12. Wei Wang · 2 shared papers, 2022–2023 · strength 0.24
  13. Joshua Leinwand · 2 shared papers, 2022–2023 · strength 0.24
  14. Gregory Lawrence Beatty · 1 shared paper, 2021 · strength 0.19
  15. Costas Andreas Lyssiotis · 1 shared paper, 2021 · strength 0.19
  16. Talia Golan · 1 shared paper, 2023 · strength 0.14
  17. Agnel Sfeir · 1 shared paper, 2023 · strength 0.14
  18. Lidong Wang · 1 shared paper, 2023 · strength 0.14
  19. Harshabad Singh · 1 shared paper, 2024 · strength 0.13
  20. Michael Lawrence Dougan · 1 shared paper, 2024 · strength 0.13
  21. Dafna Bar‐Sagi · 1 shared paper, 2024 · strength 0.13
  22. Leah H. Biller · 1 shared paper, 2024 · strength 0.13
  23. Douglas Adam Rubinson · 1 shared paper, 2024 · strength 0.13
  24. Victoire Cardot‐Ruffino · 1 shared paper, 2024 · strength 0.13
  25. Rishi Surana · 1 shared paper, 2024 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.